

Interview Summary

Application No.	Applicant(s)
08/86599	PRIEWE ET AL.
Carlos A. Azpuru	Art Unit 1615

All participants (applicant, applicant's representative, PTO personnel):

(1) Carlos A. Azpuru.

(2) James G Rueland.

Date of Interview: 8/27/03

Type: a) Telephonic b) Video Conference
c) Personal [copy given to: 1) applicant

2) [] applicant's representative]

Exhibit shown or demonstration conducted: d) Yes
If Yes, brief description: e) X No

Claim(s) discussed: N/A

Identification of prior art discussed: Goldstein, Clark et al. Knappa 1,634,649

Agreement with respect to the claims f) was reached
g) is not reached. h) N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: _____.

(A fuller description, if necessary, and a copy of the amendment which the examiner agreed would render the claims allowable, if available, must be attached. Also, where an amendment is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION IS DUE ONE MONTH FROM THIS DATE. IF NO FORMAL WRITTEN REPLY IS MADE, THE EXAMINER WILL FILE A STMENT OF DISAGREEMENT WITH RESPECT TO THE CLAIMS IN THE OFFICE ACTION.

CHANGES WHICH THE EXAMINER AGREED WOULD RENDER THE CLAIMS ALLOWABLE, IF ANY, MUST BE MADE IN THE AMENDMENTS THAT WOULD RENDER THE CLAIMS ALLOWABLE. THE SUBSTANCE OF THE INTERVIEW IS THE SUBJECT OF THIS INTERVIEW SUMMARY FORM. WHICH EVER IS LATER, TO FILE A STATEMENT OF DISAGREEMENT WITH RESPECT TO THE CLAIMS IN THE OFFICE ACTION. See Summary of Record of Interview requirements on reverse side of this sheet.

Applicability of In re Baird was discussed. It was agreed that this case was more pertinent than In re Dillon. The facts of the case with respect to the working "preferably or optimally" will be compared to that of the instant case.

The selection of the preferred copolyacrylates was also discussed. Applicant argues that the products of the biodegradation of the claimed polymers are biactive as antiproliferative agents. Support for this has not been determined. If supported, applicant may submit a declaration. Examiner's Note: You must sign this form if you plan to attach it to a signed Office action.

Examiner's signature, if required